<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528254</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A23156</org_study_id>
    <secondary_id>2011-003712-23</secondary_id>
    <nct_id>NCT01528254</nct_id>
  </id_info>
  <brief_title>VERIFY:A Study to Compare Combination Regimen With Vildagliptin &amp; Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin &amp; Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether the initiation of a vildagliptin plus
      metformin combination regimen would result in more durable glycemic control than metformin
      monotherapy in treatment-naïve patients with type-2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-center, double-blind, placebo-controlled, 2-arm, parallel group study with a
      run-in period and up to 5 years treatment period. Following a screening visit (Visit 1) and a
      screening period of up to 2 weeks, treatment-naïve patients, meeting all eligibility criteria
      entered the run-in period at Visit 2.

        -  Run-in period: At Visit 2, in all eligible patients, metformin treatment was initiated
           and/or up-titrated. At the end of the 3-week run-in period, patients who were able to
           tolerate a total dose of at least 1000 mg and up to 2000 mg daily proceeded to
           randomization and started in Period 1.

        -  Period 1 (vildagliptin/metformin combination versus metformin): At Visit 3, patients
           were randomized 1:1 to one of the following study regimens:

             -  Metformin up to 1000 mg bid plus vildagliptin 50mg bid or

             -  Metformin up to 1000 mg bid plus matching placebo bid

      The duration of Period 1 could differ between patients depending on the time when the second
      of two HbA1c measurements taken at two consecutive visits after randomisation confirmed HbA1c
      ≥ 7.0%.

      • Period 2 (vildagliptin/metformin combination versus vildagliptin add-on to metformin): In
      the case of two consecutive HbA1c measurements ≥7.0% from two consecutive study visits during
      Period 1, patients who were randomised to the placebo arm in Period 1 received vildagliptin
      50 mg bid. Patients who were randomised to the active vildagliptin 50 mg bid arm in Period 1
      continued to receive vildagliptin 50 mg bid. All patients continued to take their metformin
      dose unchanged. Period 2 remained masked to the patient and both patients and investigators
      remained masked to the treatment allocation in Period 1.

      If, during Period 2, therapy intensification was required in accordance with the local
      guidelines, the patient entered Period 3. The duration of Period 2 could differ between
      patients. End of Period 2 was considered when insulin treatment was initiated, or
      alternatively when the patient was discontinued because insulin treatment was not initiated
      in Period 3.

      • Period 3 (insulin initiation): In Period 3, patients were to be initiated on open-label
      insulin. The study drug regimen continued unchanged and remained masked to the patient in
      Period 3 and both patients and investigators remained masked to the treatment allocation in
      Period 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2012</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">April 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Initial Treatment Failure</measure>
    <time_frame>Visit 4 (Week 13) up to End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
    <description>Treatment failure was defined as two consecutive scheduled visits with HbA1c &gt;= 7.0% (starting from 13 weeks after randomization) and the time to treatment failure was the number of days from randomization to the second of the consecutive scheduled visits.
Participants who discontinued the study for any reason during Period 1 were censored at the date of discontinuation. Participants who remained under the threshold (or whose measurement above the threshold was not confirmed at next scheduled visit) were censored at the date of last study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Loss in Glycemic Control During Period 1</measure>
    <time_frame>Visit 5 (Week 26) to End of Period 1</time_frame>
    <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from Week 26 up to and including the end of Period 1 visit was included in the analysis. Baseline HbA1c was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement was missing. End of Period 1 was defined as the final post-baseline assessment obtained at any visit within Period 1 (scheduled or unscheduled), up to the last scheduled visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Loss in Glycemic Control in HbA1c Over Time During Period 2</measure>
    <time_frame>From 26 weeks after start of Period 2 to end of Period 2</time_frame>
    <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from 26 weeks after the start of Period 2 to the end of Period 2 were included in the analysis, for participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) During Period 1</measure>
    <time_frame>Visit 5 (Week 26) to End of Period 1</time_frame>
    <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from Week 26 to the end of Period 1 was included in the analysis. Baseline FPG was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) Over Time During Period 2</measure>
    <time_frame>From 26 weeks after start of Period 2 to end of Period 2</time_frame>
    <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from 26 weeks after the start of Period 2 to then end of Period 2 was included in the analysis. Only participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3 were included. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Loss of Beta Cell Function From Baseline to End of Study</measure>
    <time_frame>Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
    <description>The rate of change of beta cell function was assessed using the slope of AUC of ISR/G over time (years) where AUC of ISR/G is defined as (Area under curve of Insulin secretion rate (derived using c-peptide))/(Area under curve of Glucose), using meal-test data from 0 to 120 minutes. Baseline AUC of ISR/G was derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements were missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Insulin Sensitivity From Baseline to End of Study</measure>
    <time_frame>Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
    <description>The rate of change of insulin sensitivity is assessed using the slope of OGIS over time (years) where Oral glucose insulin sensitivity (OGIS) was calculated as a function of glucose and insulin, using meal-test data from 0 to 120 minutes. Baseline OGIS is derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements are missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events, Serious Adverse Events and Death</measure>
    <time_frame>From first dose of study treatment until End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
    <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) in each treatment arm to demonstrate that LAF237 is safe for the treatment of naïve patients with type 2 diabetes mellitus through the monitoring of relevant clinical and laboratory safety parameters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2001</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Vilda 50mg bid + metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin + vildagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin + Placebo of vildagliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of vildagliptin</intervention_name>
    <arm_group_label>Placebo + metformin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.</description>
    <arm_group_label>Vilda 50mg bid + metformin</arm_group_label>
    <other_name>LAF237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Twice daily (bid) regimen during or after meals at the same time as vildagliptin.</description>
    <arm_group_label>Placebo + metformin</arm_group_label>
    <arm_group_label>Vilda 50mg bid + metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Type 2 Diabetes Mellitus (T2DM) diagnosed ≤ 24 months ago

          -  glycosylated hemoglobin (HbA1c) ≥6.5% and ≤7.5% at Visit 1

          -  Treatment-naïve.

          -  Body mass index (BMI) ≥22 and ≤40 kg/m2 at Visit 1

        Key Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Fasting plasma glucose (FPG) ≥ 270 mg/dL (≥ 15.0 mmol/L)

          -  Previous or current participation in any vildagliptin clinical study.

          -  History of hypersensitivity to dipeptidyl peptidase-4 (DPP-4) inhibitors.

          -  Concurrent medical condition that may interfere with the interpretation of efficacy
             and safety data during the study.

          -  Donation of blood or significant blood loss equaling to at least one unit of blood
             within the past 2 weeks of start of study or a blood transfusion within the past 12
             weeks or planned regular transfusions during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Capital Federal</state>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <zip>2100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woy Woy</city>
        <state>New South Wales</state>
        <zip>2256</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morayfield</city>
        <state>Queensland</state>
        <zip>4506</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60170-320</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74935-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belem</city>
        <state>PA</state>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80810-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90430 001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mogi das Cruzes</city>
        <state>SP</state>
        <zip>08780-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01224-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazanlak</city>
        <zip>6100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Razgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruse</city>
        <zip>7200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolian</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cartagena</city>
        <state>Bolivar</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moravska Ostrava</city>
        <state>Czech Republic</state>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisek</city>
        <state>Czech Republic</state>
        <zip>397 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 5</city>
        <state>Czech Republic</state>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brandys Nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>709 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>149 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Republica Dominicana</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saku</city>
        <zip>75501</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11315</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11911</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13415</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lahti</city>
        <state>Suomi</state>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kerava</city>
        <zip>04200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kouvola</city>
        <zip>45100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>FIN-60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hainstadt</city>
        <state>Hainburg</state>
        <zip>63512</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45329</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esslingen am Neckar</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelnhausen</city>
        <zip>63571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kamp-Lintfort</city>
        <zip>47475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Ingbert - Oberwuerzbach</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viernheim</city>
        <zip>68519</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clinica</city>
        <zip>605</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>010014</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HongKong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1042</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1212</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Csongrad</city>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <zip>H-3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalocsa</city>
        <zip>6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H 6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>H 8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682 041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chandigarh</city>
        <zip>160 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91192</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sefad</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6209804</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Giborim, Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montichiari</city>
        <state>BS</state>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arenzano</city>
        <state>GE</state>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Casorate Primo</city>
        <state>PV</state>
        <zip>27022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uijeongbu-Si</city>
        <state>Gyeonggi-do</state>
        <zip>480-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jelgava</city>
        <state>LV</state>
        <zip>3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liepaja</city>
        <state>LV</state>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogre</city>
        <state>LV</state>
        <zip>5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talsi</city>
        <state>LV</state>
        <zip>3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuldiga</city>
        <zip>LV-3300</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1057</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <state>LT</state>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jonava</city>
        <zip>55268</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>51270</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kota Bahru</city>
        <state>Kelantan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad De Mexico</city>
        <state>Distrito Federal</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico D.F</city>
        <state>Distrito Federal</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>03800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cuautla</city>
        <state>Morelos</state>
        <zip>62746</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Querétaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Enebakk</city>
        <zip>1912</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fetsund</city>
        <zip>1900</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honefoss</city>
        <zip>3515</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spikkestad</city>
        <zip>3430</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <zip>0834-01862</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trujillo</city>
        <state>La Libertad</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chorrillos</city>
        <state>Lima</state>
        <zip>09</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdalena</city>
        <state>Lima</state>
        <zip>17</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marikina</city>
        <state>Metro Manila</state>
        <zip>1810</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marikina City</city>
        <zip>1800</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasay City</city>
        <zip>1300</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasig City</city>
        <zip>1600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan City</city>
        <zip>1500</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-821</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-251</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410001</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oradea</city>
        <state>Jud. Bihor</state>
        <zip>410619</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ploiesti</city>
        <state>Jud. Prahova</state>
        <zip>100097</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020045</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.- Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <state>Slovak Republic</state>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namestovo</city>
        <state>Slovak Republic</state>
        <zip>02901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roznava</city>
        <state>Slovak Republic</state>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sala</city>
        <state>Slovak Republic</state>
        <zip>92701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trebisov</city>
        <state>Slovak Republic</state>
        <zip>075 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <state>Slovak Republic</state>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nové Zámky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabinov</city>
        <zip>08301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sered</city>
        <zip>92601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sturovo</city>
        <zip>94301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alberton</city>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>1820</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2188</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>1022</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Adria Del Besos</city>
        <state>Barcelona</state>
        <zip>08930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Coloma De Gramanet</city>
        <state>Barcelona</state>
        <zip>08921</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hsintien</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Diskapi / Ankara</city>
        <zip>06770</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34304</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kahramanmaras</city>
        <zip>46100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Dominican Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Ecuador</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2020</results_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Vildagliptin</keyword>
  <keyword>Elderly Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01528254/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01528254/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>It was planned to screen approximately 4000 patients in order to randomize 2000 patients. Actually, 2001 patients were randomized, 998 patients into the Vilda 50mg bid + metformin group and 1003 into the placebo + metformin group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vilda 50mg Bid + Metformin</title>
          <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Metformin</title>
          <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="998"/>
                <participants group_id="P2" count="1003"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="998"/>
                <participants group_id="P2" count="1001"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="983"/>
                <participants group_id="P2" count="989"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period 1</title>
              <participants_list>
                <participants group_id="P1" count="458"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period 2</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period 3</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="811"/>
                <participants group_id="P2" count="787"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="216"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New therapy for study indication</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vilda 50mg Bid + Metformin</title>
          <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Metformin</title>
          <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="998"/>
            <count group_id="B2" value="1003"/>
            <count group_id="B3" value="2001"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="9.54"/>
                    <measurement group_id="B2" value="54.6" spread="9.24"/>
                    <measurement group_id="B3" value="54.3" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="545"/>
                    <measurement group_id="B2" value="515"/>
                    <measurement group_id="B3" value="1060"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="488"/>
                    <measurement group_id="B3" value="941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="605"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="1217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>glycosylated hemoglobin (HbA1c)</title>
          <description>Baseline HbA1c is the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing.</description>
          <population>Only patients with at least one measurement on or prior to Day 1 are included.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="996"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="1999"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="0.45"/>
                    <measurement group_id="B2" value="6.7" spread="0.47"/>
                    <measurement group_id="B3" value="6.7" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting plasma glucose (FPG)</title>
          <description>Baseline FPG is the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing.</description>
          <population>Only patients with at least one measurement on or prior to Day 1 are included.</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="996"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="1999"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="1.40"/>
                    <measurement group_id="B2" value="7.2" spread="1.47"/>
                    <measurement group_id="B3" value="7.1" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of type 2 diabetes</title>
          <description>Duration of type 2 diabetes is collected on the day of the screening measurement (Week -5, Visit 1)</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="7.00"/>
                    <measurement group_id="B2" value="6.6" spread="8.05"/>
                    <measurement group_id="B3" value="6.4" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate (Modification of Diet in Renal Disease)</title>
          <description>GFR (MDRD) = GFR estimated using the MDRD formula. Baseline GFR is calculated using the serum creatinine and body weight value at the Day 1 measurement, or the value obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing. Age is the value at screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal (&gt;80)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="660"/>
                    <measurement group_id="B2" value="661"/>
                    <measurement group_id="B3" value="1321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (&gt;=50 - &lt;=80)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="670"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (&gt;=30 - &lt;50)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (&lt;30)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Is subject a current smoker?</title>
          <description>Smoking status is collected on the day of the screening measurement (Week -5, Visit 1)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="998"/>
                    <count group_id="B2" value="1003"/>
                    <count group_id="B3" value="2001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Is subject a current smoker?=Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Is subject a current smoker?=No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="844"/>
                    <measurement group_id="B2" value="867"/>
                    <measurement group_id="B3" value="1711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Initial Treatment Failure</title>
        <description>Treatment failure was defined as two consecutive scheduled visits with HbA1c &gt;= 7.0% (starting from 13 weeks after randomization) and the time to treatment failure was the number of days from randomization to the second of the consecutive scheduled visits.
Participants who discontinued the study for any reason during Period 1 were censored at the date of discontinuation. Participants who remained under the threshold (or whose measurement above the threshold was not confirmed at next scheduled visit) were censored at the date of last study visit.</description>
        <time_frame>Visit 4 (Week 13) up to End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initial Treatment Failure</title>
          <description>Treatment failure was defined as two consecutive scheduled visits with HbA1c &gt;= 7.0% (starting from 13 weeks after randomization) and the time to treatment failure was the number of days from randomization to the second of the consecutive scheduled visits.
Participants who discontinued the study for any reason during Period 1 were censored at the date of discontinuation. Participants who remained under the threshold (or whose measurement above the threshold was not confirmed at next scheduled visit) were censored at the date of last study visit.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Rate (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="989"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 13-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" lower_limit="6.28" upper_limit="9.70"/>
                    <measurement group_id="O2" value="19.97" lower_limit="17.58" upper_limit="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.79" lower_limit="15.49" upper_limit="20.38"/>
                    <measurement group_id="O2" value="34.67" lower_limit="31.72" upper_limit="37.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.24" lower_limit="28.35" upper_limit="34.33"/>
                    <measurement group_id="O2" value="48.31" lower_limit="45.12" upper_limit="51.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.84" lower_limit="36.74" upper_limit="43.11"/>
                    <measurement group_id="O2" value="59.29" lower_limit="56.08" upper_limit="62.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.41" lower_limit="43.20" upper_limit="49.74"/>
                    <measurement group_id="O2" value="66.57" lower_limit="63.43" upper_limit="69.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; Year 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="429"/>
                    <count group_id="O2" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.67" lower_limit="44.29" upper_limit="61.58"/>
                    <measurement group_id="O2" value="74.39" lower_limit="68.39" upper_limit="80.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Loss in Glycemic Control During Period 1</title>
        <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from Week 26 up to and including the end of Period 1 visit was included in the analysis. Baseline HbA1c was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement was missing. End of Period 1 was defined as the final post-baseline assessment obtained at any visit within Period 1 (scheduled or unscheduled), up to the last scheduled visit.</description>
        <time_frame>Visit 5 (Week 26) to End of Period 1</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Loss in Glycemic Control During Period 1</title>
          <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from Week 26 up to and including the end of Period 1 visit was included in the analysis. Baseline HbA1c was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement was missing. End of Period 1 was defined as the final post-baseline assessment obtained at any visit within Period 1 (scheduled or unscheduled), up to the last scheduled visit.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="989"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.01"/>
                    <measurement group_id="O2" value="0.27" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Loss in Glycemic Control in HbA1c Over Time During Period 2</title>
        <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from 26 weeks after the start of Period 2 to the end of Period 2 were included in the analysis, for participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
        <time_frame>From 26 weeks after start of Period 2 to end of Period 2</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Loss in Glycemic Control in HbA1c Over Time During Period 2</title>
          <description>The rate of loss in glycemic control was estimated using the slope of HbA1c over time (years).
HbA1c data collected from 26 weeks after the start of Period 2 to the end of Period 2 were included in the analysis, for participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="588"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.15"/>
                    <measurement group_id="O2" value="1.02" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.635</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) During Period 1</title>
        <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from Week 26 to the end of Period 1 was included in the analysis. Baseline FPG was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
        <time_frame>Visit 5 (Week 26) to End of Period 1</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) During Period 1</title>
          <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from Week 26 to the end of Period 1 was included in the analysis. Baseline FPG was the sample obtained on day 1, or the sample obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurement is missing. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="989"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.01"/>
                    <measurement group_id="O2" value="0.26" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) Over Time During Period 2</title>
        <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from 26 weeks after the start of Period 2 to then end of Period 2 was included in the analysis. Only participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3 were included. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
        <time_frame>From 26 weeks after start of Period 2 to end of Period 2</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) Over Time During Period 2</title>
          <description>Rate of loss in glycemic control was estimated using the slope of FPG over time (years).
FPG (fasting plasma glucose) data from 26 weeks after the start of Period 2 to then end of Period 2 was included in the analysis. Only participants who started insulin therapy in Period 3 or discontinued during Period 2 due to being unable or unwilling to initiate insulin therapy in period 3 were included. Participants who completed the study in Period 1 or Period 2 were not be included in the analysis.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="588"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.25"/>
                    <measurement group_id="O2" value="0.99" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.381</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Loss of Beta Cell Function From Baseline to End of Study</title>
        <description>The rate of change of beta cell function was assessed using the slope of AUC of ISR/G over time (years) where AUC of ISR/G is defined as (Area under curve of Insulin secretion rate (derived using c-peptide))/(Area under curve of Glucose), using meal-test data from 0 to 120 minutes. Baseline AUC of ISR/G was derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements were missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
        <time_frame>Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
        <population>Full Analysis Set (FAS) meal-test subset</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Loss of Beta Cell Function From Baseline to End of Study</title>
          <description>The rate of change of beta cell function was assessed using the slope of AUC of ISR/G over time (years) where AUC of ISR/G is defined as (Area under curve of Insulin secretion rate (derived using c-peptide))/(Area under curve of Glucose), using meal-test data from 0 to 120 minutes. Baseline AUC of ISR/G was derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements were missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
          <population>Full Analysis Set (FAS) meal-test subset</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Week 13 to end of Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.15"/>
                    <measurement group_id="O2" value="-0.53" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Week 13 to end of Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.14"/>
                    <measurement group_id="O2" value="-0.43" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Week 13 to end of study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="0.15"/>
                    <measurement group_id="O2" value="-0.46" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of Period 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of Period 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of study</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Insulin Sensitivity From Baseline to End of Study</title>
        <description>The rate of change of insulin sensitivity is assessed using the slope of OGIS over time (years) where Oral glucose insulin sensitivity (OGIS) was calculated as a function of glucose and insulin, using meal-test data from 0 to 120 minutes. Baseline OGIS is derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements are missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
        <time_frame>Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
        <population>Full Analysis Set (FAS) meal-test subset</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Insulin Sensitivity From Baseline to End of Study</title>
          <description>The rate of change of insulin sensitivity is assessed using the slope of OGIS over time (years) where Oral glucose insulin sensitivity (OGIS) was calculated as a function of glucose and insulin, using meal-test data from 0 to 120 minutes. Baseline OGIS is derived based on samples obtained on day 1, or samples obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if the Day 1 measurements are missing. Three analyses were included, using data from Week 13 to the end of Period 1, end of Period 2 and end of study, respectively.</description>
          <population>Full Analysis Set (FAS) meal-test subset</population>
          <units>Rate (%)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Week 13 to end of Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.61" spread="1.38"/>
                    <measurement group_id="O2" value="0.41" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Week 13 to end of Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.07" spread="1.20"/>
                    <measurement group_id="O2" value="-0.99" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Week 13 to end of study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.39" spread="1.15"/>
                    <measurement group_id="O2" value="-1.01" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of Period 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-5.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.26</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of Period 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-5.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.46</ci_lower_limit>
            <ci_upper_limit>-1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>From Week 13 to end of study</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-5.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.61</ci_lower_limit>
            <ci_upper_limit>-2.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events, Serious Adverse Events and Death</title>
        <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) in each treatment arm to demonstrate that LAF237 is safe for the treatment of naïve patients with type 2 diabetes mellitus through the monitoring of relevant clinical and laboratory safety parameters.</description>
        <time_frame>From first dose of study treatment until End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)</time_frame>
        <population>Safety Set (SAF). Percentages are based on the number of patients starting each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Vilda 50mg Bid + Metformin</title>
            <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Metformin</title>
            <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events, Serious Adverse Events and Death</title>
          <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) in each treatment arm to demonstrate that LAF237 is safe for the treatment of naïve patients with type 2 diabetes mellitus through the monitoring of relevant clinical and laboratory safety parameters.</description>
          <population>Safety Set (SAF). Percentages are based on the number of patients starting each period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="998"/>
                <count group_id="O2" value="1001"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On-treatment Adverse Event (AEs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="833"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5"/>
                    <measurement group_id="O2" value="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment Serious Adverse Event (SAEs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment Deaths</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 75.6 months.</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. Maximum exposure to study treatments = 75.6 months (Vilda 50mg bid + metformin arm) and 66.2 months (Placebo + metformin arm).</desc>
      <group_list>
        <group group_id="E1">
          <title>Vilda 50mg Bid + Metformin</title>
          <description>vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Metformin</title>
          <description>Placebo of vildagliptin (Vilda 50mg bid) + Metformin</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="349" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital intestinal malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastrointestinal erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic echinococciasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pancreas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Viral myelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Traumatic arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cystadenocarcinoma ovary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gallbladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Malignant splenic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Oligoastrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Refractory cytopenia with multilineage dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Undifferentiated sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pregnancy with contraceptive device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Cervical cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Endometrial thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Ovarian fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Laryngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Skin ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="582" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="566" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1148" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="1999"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="154" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="998"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="227" subjects_at_risk="1999"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

